|
|
| | Ramucirumab Basic information |
| Product Name: | Ramucirumab | | Synonyms: | Ramucirumab;Ramucirumab,NSCLC,non–small-cell lung cancer,gastric cancer,Inhibitor,VEGFR,Vascular endothelial growth factor receptor,inhibit,angiogenesis inhibitor;Cyramza;IMC-1121B;LY3009806;Ramucirumab (anti-VEGFR2) | | CAS: | 947687-13-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ramucirumab Structure]() |
| | Ramucirumab Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | Ramucirumab Usage And Synthesis |
| Clinical Use | Human monoclonal antibody:
Treatment of advanced gastric cancer or gastrooesophageal junction adenocarcinoma, colorectal
cancer and non-small cell lung cancer (NSLC) | | target | VEGFR2 | | Drug interactions | Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | | Metabolism | The metabolism of ramucirumab has not been studied.
Monoclonal antibodies are mainly cleared by catabolism. |
| | Ramucirumab Preparation Products And Raw materials |
|